ArticleMolecular pharmacology2023
Gait Abnormalities and Aberrant D2 Receptor Expression and Signaling in Mice Carrying the Human Pathogenic Mutation
Open access · greenAbstract read
In one paragraph
Article in Molecular pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 50% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 3 citations in OpenAlex.
- Mice carrying the human dopamine D2 receptor pathogenic mutation p.Met374Arg exhibit hyperactivity and aberrant D2 receptor function.Molecular pharmacology · 2025Article
- Comparison of the function of two novel human dopamine D2 receptor variants identifies a likely mechanism for their pathogenicity.Biochemical pharmacology · 2024Article
- Necroptosis-related KLRB1 was a potent tumor suppressor and immunotherapy determinant in breast cancer.Heliyon · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 2 countries.
Dayana Rodriguez-ContrerasResearch Service, VA Portland Health Care System, Portland, Oregon (D.R.-C., T.J.P., K.A.N.); Department of Behavioral Neuroscience (D.R.-C., T.J.P., K.A.N.), Transgenic Mouse Models Shared Resource (L.M.F.), and Vollum Institute (J.J.L., J.T.W.), Oregon Health & Science University, Portland, Oregon; Department of Pharmacology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado (S.G., C.P.F.); Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, Ohio (S.G., C.P.F.); and New York University Abu Dhabi, Saadiyat Island, Abu Dhabi, United Arab Emirates (N.A., T.M.D.).
Sheng GongResearch Service, VA Portland Health Care System, Portland, Oregon (D.R.-C., T.J.P., K.A.N.); Department of Behavioral Neuroscience (D.R.-C., T.J.P., K.A.N.), Transgenic Mouse Models Shared Resource (L.M.F.), and Vollum Institute (J.J.L., J.T.W.), Oregon Health & Science University, Portland, Oregon; Department of Pharmacology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado (S.G., C.P.F.); Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, Ohio (S.G., C.P.F.); and New York University Abu Dhabi, Saadiyat Island, Abu Dhabi, United Arab Emirates (N.A., T.M.D.).
Joseph J LebowitzResearch Service, VA Portland Health Care System, Portland, Oregon (D.R.-C., T.J.P., K.A.N.); Department of Behavioral Neuroscience (D.R.-C., T.J.P., K.A.N.), Transgenic Mouse Models Shared Resource (L.M.F.), and Vollum Institute (J.J.L., J.T.W.), Oregon Health & Science University, Portland, Oregon; Department of Pharmacology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado (S.G., C.P.F.); Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, Ohio (S.G., C.P.F.); and New York University Abu Dhabi, Saadiyat Island, Abu Dhabi, United Arab Emirates (N.A., T.M.D.).
Lev M FedorovResearch Service, VA Portland Health Care System, Portland, Oregon (D.R.-C., T.J.P., K.A.N.); Department of Behavioral Neuroscience (D.R.-C., T.J.P., K.A.N.), Transgenic Mouse Models Shared Resource (L.M.F.), and Vollum Institute (J.J.L., J.T.W.), Oregon Health & Science University, Portland, Oregon; Department of Pharmacology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado (S.G., C.P.F.); Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, Ohio (S.G., C.P.F.); and New York University Abu Dhabi, Saadiyat Island, Abu Dhabi, United Arab Emirates (N.A., T.M.D.).
Naeem AsadResearch Service, VA Portland Health Care System, Portland, Oregon (D.R.-C., T.J.P., K.A.N.); Department of Behavioral Neuroscience (D.R.-C., T.J.P., K.A.N.), Transgenic Mouse Models Shared Resource (L.M.F.), and Vollum Institute (J.J.L., J.T.W.), Oregon Health & Science University, Portland, Oregon; Department of Pharmacology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado (S.G., C.P.F.); Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, Ohio (S.G., C.P.F.); and New York University Abu Dhabi, Saadiyat Island, Abu Dhabi, United Arab Emirates (N.A., T.M.D.).
Timothy M DoreResearch Service, VA Portland Health Care System, Portland, Oregon (D.R.-C., T.J.P., K.A.N.); Department of Behavioral Neuroscience (D.R.-C., T.J.P., K.A.N.), Transgenic Mouse Models Shared Resource (L.M.F.), and Vollum Institute (J.J.L., J.T.W.), Oregon Health & Science University, Portland, Oregon; Department of Pharmacology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado (S.G., C.P.F.); Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, Ohio (S.G., C.P.F.); and New York University Abu Dhabi, Saadiyat Island, Abu Dhabi, United Arab Emirates (N.A., T.M.D.).
Tamara J PhillipsResearch Service, VA Portland Health Care System, Portland, Oregon (D.R.-C., T.J.P., K.A.N.); Department of Behavioral Neuroscience (D.R.-C., T.J.P., K.A.N.), Transgenic Mouse Models Shared Resource (L.M.F.), and Vollum Institute (J.J.L., J.T.W.), Oregon Health & Science University, Portland, Oregon; Department of Pharmacology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado (S.G., C.P.F.); Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, Ohio (S.G., C.P.F.); and New York University Abu Dhabi, Saadiyat Island, Abu Dhabi, United Arab Emirates (N.A., T.M.D.).ORCID 0000-0002-7350-6323
Christopher P FordResearch Service, VA Portland Health Care System, Portland, Oregon (D.R.-C., T.J.P., K.A.N.); Department of Behavioral Neuroscience (D.R.-C., T.J.P., K.A.N.), Transgenic Mouse Models Shared Resource (L.M.F.), and Vollum Institute (J.J.L., J.T.W.), Oregon Health & Science University, Portland, Oregon; Department of Pharmacology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado (S.G., C.P.F.); Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, Ohio (S.G., C.P.F.); and New York University Abu Dhabi, Saadiyat Island, Abu Dhabi, United Arab Emirates (N.A., T.M.D.).
John T WilliamsResearch Service, VA Portland Health Care System, Portland, Oregon (D.R.-C., T.J.P., K.A.N.); Department of Behavioral Neuroscience (D.R.-C., T.J.P., K.A.N.), Transgenic Mouse Models Shared Resource (L.M.F.), and Vollum Institute (J.J.L., J.T.W.), Oregon Health & Science University, Portland, Oregon; Department of Pharmacology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado (S.G., C.P.F.); Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, Ohio (S.G., C.P.F.); and New York University Abu Dhabi, Saadiyat Island, Abu Dhabi, United Arab Emirates (N.A., T.M.D.).
Kim A NeveResearch Service, VA Portland Health Care System, Portland, Oregon (D.R.-C., T.J.P., K.A.N.); Department of Behavioral Neuroscience (D.R.-C., T.J.P., K.A.N.), Transgenic Mouse Models Shared Resource (L.M.F.), and Vollum Institute (J.J.L., J.T.W.), Oregon Health & Science University, Portland, Oregon; Department of Pharmacology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado (S.G., C.P.F.); Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, Ohio (S.G., C.P.F.); and New York University Abu Dhabi, Saadiyat Island, Abu Dhabi, United Arab Emirates (N.A., T.M.D.) nevek@ohsu.edu.ORCID 0000-0003-0109-7345
New York University Abu Dhabi · AE
Funding
BIOLOGICAL BASES OF DRUG-SEEKING BEHAVIORT32DA007262 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI WILLIAMS, JOHN T · 1991 to 2022
$9.4MCOCAINE: EFFECTS ON SINGLE NEURONSR01DA004523 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI WILLIAMS, JOHN T · 1987 to 2025
$7.6MEncoding Dopamine Signals in the Mesolimbic SystemR01DA035821 · NIDA · UNIVERSITY OF COLORADO DENVER · PI FORD, CHRISTOPHER PETER · 2013 to 2023
$3.5MGenetic Risk for Methamphetamine AbuseU01DA041579 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI PHILLIPS, TAMARA J. · 2016 to 2020
$2.1MGenetic Factors Underlying Risk for Methamphetamine Intake and Associated TraitsR01DA046081 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI PHILLIPS, TAMARA J. · 2018 to 2022
$1.7MStress induced plasticity of excitatory inputs to the LCR21MH123085 · NIMH · UNIVERSITY OF COLORADO DENVER · PI FORD, CHRISTOPHER PETER · 2020 to 2020
$428kCharacterization of a DRD2 Variant that is Associated With a Movement DisorderR21NS117713 · NINDS · OREGON HEALTH & SCIENCE UNIVERSITY · PI NEVE, KIM ARTHUR · 2020 to 2020
$345kDopamine D2 Receptor Mutations and Hyperkinetic Movement DisordersI01BX005986 · VA · PORTLAND VA MEDICAL CENTER · PI NEVE, KIM ARTHUR · 2022 to 2025
–BLRD VA I01 BX003279BLRD VA I01 BX005986BLRD VA IK6 BX006342NIDA NIH HHS R01 DA004523NIDA NIH HHS R01 DA035821NIDA NIH HHS R01 DA046081NIDA NIH HHS T32 DA007262NIDA NIH HHS U01 DA041579NIMH NIH HHS R21 MH123085NINDS NIH HHS R21 NS117713
Abstract
A dopamine D2 receptor mutation was recently identified in a family with a novel hyperkinetic movement disorder. That allelic variant D2-I
Indexed as
DopamineMovement DisordersReceptors, Dopamine D2AnimalsDopaminergic NeuronsGaitHumansHyperkinesisMiceMutationSulpirideDopamineDRD2 protein, humanDRD2 protein, mouseReceptors, Dopamine D2Sulpiride
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.